Part D Premiums ‘Won’t Go Up’ With HHS Rebate Proposal, Azar Maintains
Executive Summary
US HHS secretary tells Senate Finance Committee he believes pharmacy benefit managers will effectively keep drug costs down in Medicare Part D, even without rebates.
You may also be interested in...
Biopharma, the White House And Getting Drug Pricing ‘Off The Table’
Industry balks at President Trump’s latest effort to force biopharma to negotiate a drug pricing solution, but investors may be pushing for concessions that could head off more onerous policies supported by a Biden White House.
One More Score: CBO Projects HHS Rebate Proposal Would Boost Part D Spending $170bn
HHS downplays latest attempt to predict “complex behavior changes to a broken system.”
Running The Gauntlet: Takeaways From The First Round Of HHS Hearings In 2019
Release of the White House budget proposal kicked off the first round of hearings on HHS with a new Democratic majority in the House and a new HHS budget czar in the Senate. HHS Secretary Azar did his best to set a constructive tone for advancing drug pricing policies – and maintaining his own position – in the year to come.